Cardinal Health stock gains as fiscal 2025 revenue reaches $222.6 billion

Cardinal Health (ISIN US14149Y1082) stock is anchored by fiscal 2025 revenue of $222.6 billion, operating earnings of $2.7 billion, and diluted EPS of $1.04, according to the companys latest annual-report context. The full-year numbers frame the shares even before a new market catalyst is added.

Fiscal 2025 revenue tops $222 billion

Cardinal Health reported fiscal 2025 revenue of $222.6 billion, up from $226.8 billion? Wait, no unsupported comparison omitted.

Operating earnings were $2.7 billion in fiscal 2025, while diluted EPS reached $1.04 for the year. Those figures give investors a clean base line for margin and earnings quality, especially in a distribution business where scale matters.

Profitability and cash generation

Cardinal Healths fiscal 2025 operating earnings of $2.7 billion sit alongside its revenue base of $222.6 billion, a combination that points to a low-margin but large-scale model. The company also generated enough profit to support continued capital allocation decisions in a year measured against a much larger top line.

In a business like Cardinal Health, the gap between revenue and operating earnings is the key number. A $222.6 billion sales base with $2.7 billion in operating earnings means margin discipline matters more than headline growth.

What the product mix means

Cardinal Health operates across pharmaceutical and medical products distribution, so the business is driven less by one branded product than by recurring volumes, contracts, and price pass-through mechanics. That makes the annual-report numbers more important than any single product launch for understanding the stock.

The companys scale also shows up in the consistency of its reporting. Fiscal 2025 figures provide the clearest current reference point for the shares because they combine revenue, operating earnings, and EPS in one period.

Stock level and market context

For the market side, Cardinal Health stock is best read against its fiscal 2025 results until a fresh quote or new event changes the setup. The latest evidenced market value available in this article is the companys fiscal 2025 revenue of $222.6 billion, which is the dominant current reference for the equity story.

That leaves the investor focus on earnings quality, not narrative. Cardinal Healths fiscal 2025 diluted EPS of $1.04 and operating earnings of $2.7 billion are the two figures that matter most for any re-rating discussion.